1998;91:2969 -76. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA -4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94:25 -39. Jaigirdar A, Rosenberg S, Parkhurst M. A high-avidity WT1-reactive T-cell receptor mediates recognition of peptide and processed antig en but not naturally occurring WT1- positive tumor cells. J Immunother.